3D Signatures Announces Positive Topline Results of Development Trial Assessing its Telo-HL Test for Hodgkin’s Lymphoma

3D Signa­­­­­­tures (TSXV:DXD) is pleased to announce that a preliminary third-party analysis of the trial data for Telo-HL, 3DS’ test in development for Hodgkin’s lymphoma (HL), shows that the Company’s TeloView platform is able to distinguish, with a high degree of statistical significance, multiple differences between a patient group that responds to standard ABVD chemotherapy, and a group that relapses or is refractory to treatment within the first 12 months.

As quoted in the press release:

“BSSI is excited to be collaborating with 3DS, helping them ensure the quality of the data being used is to the highest standards, and that they are poised to deliver the best possible analysis of this predictive technology for HL treatment,” said Ronald L. Bromley, CEO of BioStat Solutions, Inc.

“We believe that these results from the application of our TeloView platform to Hodgkin’s lymphoma are so strong, the Company will now even more confidently proceed with developing the final scoring model for its Telo-HL test to predict response at the individual patient level,” said Jason Flowerday, CEO of 3D Signatures. “This is great news for the Telo-HL program, and we remain on track to complete all phases of the test development and analytical validation by April 2018.”

Click here to read the full press release.